A Network Meta-Analysis on Randomized Trials Focusing on the Preventive Effect of Statins on Contrast-Induced Nephropathy

Abstract EN

Contrast-induced nephropathy is a common complication of iodinated contrast administration.

Statins may reduce the risk of contrast-induced nephropathy, but data remain inconclusive.

We summarized the evidence based on statins for the prevention of contrast-induced nephropathy with a network meta-analysis.

Randomized trials focusing on statins were searched and pooled with random-effect odds ratios.

A total of 14 trials (6,160 patients) were included, focusing on atorvastatin (high/low dose), rosuvastatin (high dose), simvastatin (high/low dose), and placebo or no statin therapy before contrast administration.

The risk of contrast-induced nephropathy was reduced by atorvastatin high dose and rosuvastatin high dose, with no difference between these two agents.

Results for atorvastatin low dose and simvastatin (high/low dose) in comparison to placebo were inconclusive.

Atorvastatin and rosuvastatin administered at high doses and before iodinated contrast administration have a consistent and beneficial preventive effect on contrast-induced nephropathy and may actually halve its incidence.